Prodrug and Formulation Technologies

Unmet Need

Many current and emerging drug therapies suffer from poor PK/PD profiles and poor bioavailability. This can result in a less desirable route of administration, a complicated oral dosing regimen, unwanted side effects, or the complete discontinuation of product development. 


TSRL, Inc. has developed drug delivery technologies to improve dose response, increase solubility, and reduce toxicity associated with extended release drugs. Our extended release formulation provides a PK/PD rational to reduce dose and toxicity of common disease states, including:

  • Cholesterol Synthesis
  • Cardiovascular Disease
  • Asthma Bronchial
  • Peptic Ulcer Disease
  • Gastric Secretion

Rational for improvement in PK/PD:

  • Circadian Rhythm: Night time maximum
  • Reduction of Metabolism: Positional expression of P450 within intestine
  • Formulation: Match maximum activity, delayed release to reduce metabolism, reduce dose and toxicity

Supported Intellectual Property (IP)

Supported IP within our drug delivery portfolio:

Name of Patent/ApplicationPatent/App. No.Filing DateExpiration Date
Controlled Release of Drugs66699541/10/20021/24/2021
Short Peptide Carrier System for Cellular Delivery of Agent717618511/24/20041/10/2025
Methods & Composition of Extended Delivery of Water Insoluble Drugs85357164/1/20054/7/2033

Supported IP within our antiviral prodrug portfolio:

Supported Intellectual PropertyApp/Patent No.Filing DateExpiration Date
Cidofovir Peptide Conjugates as Prodrugs75110517/1/20053/12/26
Phosphonyl Ester Conjugates as Prodrugs80632093/16/200910/13/25
Tyrosine-based Prodrugs of Antiviral Agents89403134/23/20115/27/31
Prodrugs of Neuraminidase Inhibitors918128111/26/201311/26/2033


For more information, contact Business Development at